These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 36513866)
1. Neuroinflammation and neovascularization in diabetic eye diseases (DEDs): identification of potential pharmacotherapeutic targets. Panda SP; Reddy PH; Gorla US; Prasanth D Mol Biol Rep; 2023 Feb; 50(2):1857-1869. PubMed ID: 36513866 [TBL] [Abstract][Full Text] [Related]
2. Vascular endothelial growth factor is present in glial cells of the retina and optic nerve of human subjects with nonproliferative diabetic retinopathy. Amin RH; Frank RN; Kennedy A; Eliott D; Puklin JE; Abrams GW Invest Ophthalmol Vis Sci; 1997 Jan; 38(1):36-47. PubMed ID: 9008628 [TBL] [Abstract][Full Text] [Related]
3. [Diabetic retinopathy--the mechanisms of the ocular neovascularization and the development of anti-angiogenic drugs]. Kuroki M; Kawakami M Nihon Rinsho; 1999 Mar; 57(3):584-9. PubMed ID: 10199138 [TBL] [Abstract][Full Text] [Related]
4. [Alternative splicing of vascular endothelial growth factor A and ocular neovascularization]. Fan SJ; He SZ Zhonghua Yan Ke Za Zhi; 2011 Apr; 47(4):373-7. PubMed ID: 21612688 [TBL] [Abstract][Full Text] [Related]
5. Poly(ADP-ribose) polymerase inhibitors counteract diabetes- and hypoxia-induced retinal vascular endothelial growth factor overexpression. Obrosova IG; Minchenko AG; Frank RN; Seigel GM; Zsengeller Z; Pacher P; Stevens MJ; Szabó C Int J Mol Med; 2004 Jul; 14(1):55-64. PubMed ID: 15202016 [TBL] [Abstract][Full Text] [Related]
7. Plasma VEGF and soluble VEGF receptor FLT-1 in proliferative retinopathy: relationship to endothelial dysfunction and laser treatment. Lip PL; Belgore F; Blann AD; Hope-Ross MW; Gibson JM; Lip GY Invest Ophthalmol Vis Sci; 2000 Jul; 41(8):2115-9. PubMed ID: 10892852 [TBL] [Abstract][Full Text] [Related]
8. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. Aiello LP; Avery RL; Arrigg PG; Keyt BA; Jampel HD; Shah ST; Pasquale LR; Thieme H; Iwamoto MA; Park JE N Engl J Med; 1994 Dec; 331(22):1480-7. PubMed ID: 7526212 [TBL] [Abstract][Full Text] [Related]
9. Attenuation of streptozotocin-induced diabetic retinopathy with low molecular weight fucoidan via inhibition of vascular endothelial growth factor. Yang W; Yu X; Zhang Q; Lu Q; Wang J; Cui W; Zheng Y; Wang X; Luo D Exp Eye Res; 2013 Oct; 115():96-105. PubMed ID: 23810809 [TBL] [Abstract][Full Text] [Related]
11. Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases. Pe'er J; Shweiki D; Itin A; Hemo I; Gnessin H; Keshet E Lab Invest; 1995 Jun; 72(6):638-45. PubMed ID: 7540233 [TBL] [Abstract][Full Text] [Related]
12. The Role of Inflammation and Therapeutic Concepts in Diabetic Retinopathy-A Short Review. Gomułka K; Ruta M Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674535 [TBL] [Abstract][Full Text] [Related]
13. Advanced glycation end products increase retinal vascular endothelial growth factor expression. Lu M; Kuroki M; Amano S; Tolentino M; Keough K; Kim I; Bucala R; Adamis AP J Clin Invest; 1998 Mar; 101(6):1219-24. PubMed ID: 9502762 [TBL] [Abstract][Full Text] [Related]